This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.
Safety Profile1
The safety profile of VENCLYXTO has been evaluated in 758 patients with CLL across 5 clinical trials (one phase I (M12-175), two phase II (M13-982 and M14-032) & two Phase III (MURANO & CLL-14) with VEN-mono, VEN+R or as VEN+O.1
ADRs, Adverse drug reactions; CLL, Chronic lymphocytic leukaemia; TLS, Tumour lysis syndrome; VEN-mono, VENCLYXTO monotherapy; VEN+O, VENCLYXTO and Obinutuzumab; VEN+R, VENCLYXTO and Rituximab.
References
- VENCLYXTO Summary of Product Characteristics.
You are advised to read the Prescribing Information and Summary of Product Characteristics to evaluate patient suitability for VENCLYXTO.
VENCLYXTO PRESCRIBING INFORMATION
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (GB)
VENCLYXTO SUMMARY OF PRODUCT CHARACTERISTICS (NI)
UK-VNCCLL-230505. Date of preparation: April 2024.
